Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

European guidelines recommend that the timing of the initiation of non-vitamin K antagonist oral anticoagulants (NOACs) for AF patients with cerebral infarction or TIA is association with stroke severity

coagulation factor
stroke
warfarin
diabetes
cerebral infarction
  • 13 views
  • 11 Feb, 2021
  • 1 location
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in …

probe
heparin
vitamin k
thromboembolism
venous thromboembolism
  • 0 views
  • 28 Jan, 2021
  • 170 locations
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score 2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral …

stroke
vitamin k
apixaban
dabigatran
anticoagulation therapy
  • 13 views
  • 23 Jan, 2021
  • 32 locations
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.

Atrial fibrillation is the most common cardiac arrhythmia. In atrial fibrillation, there is a risk that clots can form in the heart, especially in the left atrium. If these clots come loose, there is a risk of stroke. To prevent strokes, patients with atrial fibrillation and status post ICB can …

atrial fibrillation
arrhythmia
anticoagulation therapy
anesthesia
fibrillation
  • 0 views
  • 24 Jan, 2021
API-CAT STUDY for APIxaban Cancer Associated Thrombosis

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with active cancer who have completed at least 6 months of anticoagulant therapy …

  • 8 views
  • 29 Jan, 2021
  • 70 locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

atrial fibrillation
vitamin k
thromboembolism
dabigatran
coronary artery bypass graft
  • 112 views
  • 24 Feb, 2021
  • 76 locations
Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist

Novel, non-vitamin K antagonist oral anticoagulants (NOAC) target selected players in the coagulation cascade as the direct thrombin inhibitor dabigatran and the factor Xa-inhibitors apixaban

noac
hematoma
apixaban
anticoagulants
rivaroxaban
  • 19 views
  • 25 Jan, 2021
  • 1 location
Use of Warfarin After the First Trimester in Pregnant Women With APS

Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid

vitamin k antagonist
antiphospholipid syndrome
heparin
vitamin
early pregnancy
  • 135 views
  • 24 Jan, 2021
  • 2 locations
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)

The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA

atrial flutter
holter monitor
chronic haemodialysis
apixaban
anticoagulation therapy
  • 6 views
  • 25 Jan, 2021
  • 3 locations
Avoiding Anticoagulation After IntraCerebral Haemorrhage

). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist

intracerebral hemorrhage
vitamin k
apixaban
anticoagulation therapy
brain ct
  • 0 views
  • 25 Jan, 2021
  • 2 locations